



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on November 13, 2006.

SUBMISSION OF SEQUENCE LISTING
UNDER 37 CFR §§1.821-1.825
Patent Application
Docket No. ARS-125
Serial No. 10/570,121

Frank C. Eisenschenk
Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ilya Chumakov, Oxana Guerassimenko
Serial No. : 10/570,121
Filed : February 28, 2006
Conf. No. : 7412
For : Novel UBP8rp Polypeptides and Their Use in the Treatment of Psoriasis

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825


Sir:

Transmitted herewith is a Sequence Listing in computer readable format under 37 CFR §§1.821 through 1.825 for the above-identified patent application. The paper copy of the Sequence Listing was submitted with the application when filed. A Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures was received from the Patent and Trademark Office which indicated that the subject application does not comply with the sequence requirements of 37 CFR §§1.821-1.825. A copy of the Notification is enclosed herewith.

I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.
Patent Attorney
Registration No. 45,332
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Enclosures: Sequence listing in computer readable format; Copy of Notification to Comply with Requirements